@CDRLifeBiotech profile picture
CDR-Life @CDRLifeBiotech

Redefining antibody therapies

Joined February 2018
  • Tweets 74
  • Following 21
  • Followers 78
45 Photos and videos
Meet Fabian Scheifele, Head of Discovery at CDR-Life šŸ§¬ For 7 years, he's led our Discovery team with passionā€”and moonlighted as our office egg dealer šŸ„ššŸš Fresh science, fresh eggs, and a love for the outdoors! #TeamTuesday #CDRLife
1
25
Check out our posters on T-cell engagers for solid tumors at #AACR2025 Chicago: CDR404 (MAGEā€‘A4) ā€“ more potent with less T-cell exhaustion than a direct competitor (Abs #3494) CDR505 (KKā€‘LCā€‘1) ā€“ firstā€‘inā€‘class, highly specific and potent (Abs #3493) bit.ly/4jMGAeb
2
35
Say hello to Sophie Barsin, our Portfolio Management expert! Her unique perspective complements our scientists' expertise, creating a balanced approach that drives project success and helps guides promising research toward meaningful outcomes. Learn more cdr-life.com
1
1
32
Pipeline Expansion: CDR111, novel trispecific molecule for immune reset in autoimmune diseases! Plus, oncology updates at #AACR25! Join us on April 28 for TCE data: Ā· CDR404 ā€“ Potential best-in-class MAGE-A4 TCE Ā· Novel TCE for HLA-A*01/KK-LC-1 tumors bit.ly/43UTVfM
1
1
174
#InternationalWomensDay! At CDR-Life, weā€™re inspiring the next generation of scientists. Our team visited Neue Schule ZĆ¼rich to share career paths, teamwork and the science behind our work. We loved meeting future female scientists!
1
1
30
Heading to Milan for BIO-Europe Spring! Our Chief Business Officer Sarah Holland will share insights on the future of T cell engagers in cancer and autoimmune disease treatmentā€”plus whatā€™s ahead for our innovative M-gagerĀ® platform. Letā€™s connect! #BIOEuropeSpring #TCellEngagers
58
Thank you Modern Retina for covering the progress of our collaboration w Boehringer Ingelheim. Weā€™ve reached our 5th milestone as BI 771716, our antibody fragment technology, advances into Ph 2 trials for geographic atrophy. Patient enrollment is underway! modernretina.com/view/cdr-liā€¦

CDR-Life completes fifth milestone and is recruiting patients for Phase 2 study of BI 771716 |...

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

modernretina.com
50
Proud to have our CBO Sarah Holland chair the Pharma Dealmakers Panel at the #Sachs_ELSF alongside leaders from @Novartis, @Roche, @GSK, @Sanofi & @Secarna discussing the future of biotech partnerships
1
31
Excited to hold our first Autoimmune Scientific Advisory Board meeting today! With CDR404's clinical progress & our new CDR111 (CD3xCD19xBCMA trispecific) for immune reset, our proprietary antibody-based M-gagerĀ® platform expands our unique T cell engager approach to autoimmunity
1
3
36
Meet Ivana Tosevski, our Head of Preclinical Safety! Ivana plays a crucial role in ensuring the safety of our molecules before they advance to clinical trials. Thank you, Ivana, for being an integral member of the CDR-Life family! Learn more about us at cdr-life.com
1
24
Biotech new year kicks off in SF! šŸŒ‰ Heading to #JPM2025 to discuss T cell engagers ā€“ an exciting approach for cancer & autoimmune therapies via our unique M-gagerĀ® platform. Reach out to chat.
90
Science People = Magic! David Stocker embodies CDR-Life's spirit. 3 years of great work in therapeutic development. Discover more about our incredible team and science: cdr-life.com
1
18
Expanding our leadership team! Sarah Holland joins CDR-Life as Chief Business Officer to drive our M-gagerĀ® platform and T cell engager therapies forward. Excited to accelerate our impact in cancer and autoimmune disease treatment. Full details: cdr-life.com/news/#latest
3
37
Geneva-bound! CDR-Life at #ESMOIO, showcasing M-gagerĀ® and CDR404 ā€“ our novel T cell engager targeting MAGE-A4 in solid tumors. Let's connect! #ESMOImmuno24
2
154
Behind game-changing clinical trials is an outstanding leader. Meet Clare Price, VP of Clinical Operations! She's advancing our M-gager platform and T cell engager therapies through expert trial management and unwavering dedication to patient safety. cdr-life.com
1
28
Looking forward to @Jefferies London Healthcare Conference! CEO Christian Leisner and CFO Konstantin von Schulthess will discuss CDR-Life's innovative T cell engager platform targeting hard-to-treat solid cancers and autoimmune diseases. Let's connect! #JefferiesHealthcare
2
66
Join us at #SITC2024! We're presenting a poster on CDR404, our innovative T cell engager targeting MAGE-A4 in solid tumors such as lung, bladder & head/neck cancers. Stop by our poster or reach out to connect!
3
85
Meet Stephanie Jungmichel, our Head of Pharmacology! Leading our cell biology research, she drives the development of our T cell engagers (M-gagerĀ®) from discovery to clinic. First in our series introducing the brilliant minds behind CDR-Life!
2
38
Stockholm calling! CDR-Life CEO Christian Leisner is attending #BIOEurope discussing the companyā€™s M-gager portfolio for solid tumors and autoimmune diseases and T cell engager therapeutics pipeline. Drop us a line if you want to connect!
1
39
It was a pleasure speaking with @Brad Loncar about our T cell engager (TCE) platform to target hard-to-treat tumors. Check out the full interview to learn about our pipeline and upcoming milestones.
BiotechTV
@BiotechTV
23 Sep 2024
From Zurich: CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue. Full video: biotechtv.com/post/cdr-life-ā€¦
2:40
2
45
Load more